Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

r POS were 53% and 65%, respectively.  The decrease in gross margin was attributable to the reduction in POS prices that the Company has instituted to increase affordability and market potential of the services being offered.

Costs of TOS for the fiscal year 2011 and 2010 were $1.5 million and $0.8 million, respectively, an increase of $0.7 million, or 93%.  For the fiscal year 2011 and 2010, gross margins for TOS was 56% and 53%, respectively.  

Research and DevelopmentResearch and development, or R&D, expenses for fiscal year 2011 and 2010 were $3.0 million and $2.6 million, respectively, an increase of $0.4 million, or 12%.  The increase in R&D expenses in 2011 was primarily due to the Company's increased spending on its technology platform and Tumorgraft testing on the company's in-licensed compounds.

General and AdministrativeGeneral and administrative, or G&A, expenses for the fiscal year 2011 and 2010 were $4.6 million and $2.8 million, respectively, an increase of $1.8 million, or 67%.  The increase was primarily due to the $2.3 million of non-cash stock-based compensation expense related to stock options issued to the Company's Chief Executive Officer and President.

Sales and MarketingSales and marketing expenses for the fiscal year 2011 and 2010 were $1.4 million and $0.5 million, respectively, and increase of $0.9 million or 173%.  The increase was primarily due to the hiring of additional sales employees and $0.3 million in new marketing efforts.

Other Income (Expense), NetOther income (expense), net for the fiscal year 2011 was $1.5 million, which primarily relates to grant income earned under the Qualifying Therapeutic Discovery Project program administered under Section 48D of the Internal Revenue Code based on the qualifying expenses incurred through the fiscal year ended April 30, 2011.

Cash and Cash EquivalentsThe Company's cash position on April 30,
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
2. Champions Biotechnology Changes Name to Champions Oncology
3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
5. Champions Biotechnology Reports Additions to its Management Team
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... DUBLIN , May 29, 2015 ... the addition of the "Global Bioinformatics Market ... The analysts forecast the global bioinformatics market to ... period 2014-2019. Bioinformatics is a field of ... which consists of information stored in DNA form ...
(Date:6/1/2015)... June 01, 2015 Sistemic Ltd. ... entered into a commercial collaboration agreement and signed ... combine their technologies and work together towards advancing ... technology. RoosterBio and Sistemic will collaborate on utilizing ... build more precise and relevant characterization panels for ...
(Date:6/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lkcspr/2015_strategies ... "2015 Strategies in European Immunoprotein Diagnostic ... This new 273-page report provides ... including emerging tests, technologies, instrumentation, sales forecasts, ... suppliers. Companies Mentioned: - ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/tdw3ss/2015_strategies ... "2015 Strategies in the UK Flow Cytometry Market" ... report presents a comprehensive analysis of the UK ... pertaining to the French flow cytometry practice, as ... technological trends with significant market impact during the ...
Breaking Biology Technology:Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4Strategies in the UK Flow Cytometry Market 2015 2
... SQUARE, Pa., Aug. 24, 2011 Kibow Biotech, Inc. ... licensing and marketing agreement with the current licensing partner ... patented, 100% natural, probiotic dietary supplement indicated for the ... to severe renal failure. Developed by Kibow, Azodyl™ has ...
... YORK, Aug. 24, 2011 Reportlinker.com announces that ... its catalogue: Strategic Analysis of ... Table of Contents ... Executive Summary 9-10 Global Biosimilar ...
... of researchers from France and Germany has developed a ... to electrical fields at room temperature. Previously this was ... temperatures. Electric fields are technically much easier and cheaper ... power guzzling coils. The researchers have now found a ...
Cached Biology Technology:Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2Strategic Analysis of Indian Biosimilar Market 2Strategic Analysis of Indian Biosimilar Market 3Controlling magnetism with electric fields 2
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... to provide visible and infrared imagery of Iceland,s Eyjafjallajokull ... the plume being pulled in a northeasterly direction over ... being pushed to the northeast from a low pressure ... Spectroradiometer or MODIS instrument that flies aboard Terra captured ...
... , ANN ARBOR, Mich. Prostate cancer treatments that target ... the wrong source, according to a new study. Researchers have ... cancer, it blocks the receptor for the hormone androgen, preventing ... the University of Michigan Comprehensive Cancer Center, suggests that the ...
... evolution took over an experimental strain of bacteria, it derailed ... conducting, but led to something much more profound instead. ... large plastic bubble, called an isolator, that was completely sterile, ... of bacteria into the mouse colony, but it mutated quickly ...
Cached Biology News:Gene fusions may be the 'smoking gun' in prostate cancer development, U-M study finds 2Quickly evolving bacteria could improve digestive health 2
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: